CRLF2 Polyclonal Antibody, Cy3 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-2727R-Cy3 |
| Product Name | CRLF2 Polyclonal Antibody, Cy3 Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CRLF2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 64109 |
| Subcellular location | Secreted, Cell membrane |
| Synonyms | TSLPR; CRLF2; CRL 2; CRL2; CRLF 2; CRLF2Y; Cytokine receptor CRL2 precusor; Cytokine receptor like 2; Cytokine receptor like factor 2; Cytokine receptor like factor 2 precursor; IL XR; ILXR; Thymic stromal derived lymphopoietin receptor; Thymic stromal lymphopoietin protein receptor; Thymic stromal lymphopoietin receptor; TSLP receptor; TSLPR. |
| Background | TSLPR is a type I membrane receptor that forms a functional heterodimeric complex with IL7R to bind TSLP. The TSLP R contains a WSXWS motif required for proper protein folding and a box1 motif important for association with the JAKs. TSLPR has a predicted molecular weight approximately 41 kD, and two further isoforms have been reported that are produced by alternative splicing. The TSLPR is expressed preferentially in myeloid cells including dendritic cells and activated monocytes, and is weakly expressed in T cells. Expression has also been reported in heart, skeletal muscle, and kidney tissues. TSLP binding to the heterodimeric functional receptor (TSLPR and IL7R) activates JAK2, STAT3 and STAT5 to stimulate cell proliferation. Ligand receptor interactions haves been implicated in the development of the hematopoietic system, dendritic cell maturation, and the maintenance and polarization of human Th2 memory T cells in allergic diseases. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is CRLF2 Polyclonal Antibody, Cy3 Conjugated (bs-2727R-Cy3) validated for, and at what dilution?
bs-2727R-Cy3 is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-2727R-Cy3 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise CRLF2 Polyclonal Antibody, Cy3 Conjugated (bs-2727R-Cy3)?
KLH conjugated synthetic peptide derived from human CRLF2
What are the excitation and emission wavelengths of the Cy3 conjugate (bs-2727R-Cy3)?
Cy3 on bs-2727R-Cy3: excitation / emission 512,550nm/570,615nm.